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Summary. This review article has described briefly 
studies supporting the concept that IL-8 expression and 
its regulation by inflammatory cytokines like IL-1 may 
play an important role in controlling the phenotypes 
associated with melanoma progression and metastasis. It 
is clear from the experiments presented here that IL-8 is 
an important autocrine multifunctional cytokine that 
modulates melanoma/cell proliferation, migration by 
induction of extracellular matrix degradation enzymes 
and induces neovascularization, all of which are critical 
for melanoma growth and metastasis. In addition, their 
expression in melanoma tumor specimens suggests an 
association between IL-8 expression and tumor 
aggressiveness. Further, inflammatory cytokines 
produced by either tumor cells or stromal cells may 
regulate IL-8 expression, which can control melanoma 
growth and enhance our current knowledge regarding 
rnelanoma progression and metastasis. Understanding 
these events and their significance will allow us to 
design novel therapeutic approaches for treatment of 
melanoma. 
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Introduction 
Human cutaneous malignant melanoma is a highly 
aggressive form of skin cancer, the incidence of which is 
increasing at a greater rate than any other type of cancer, 
and for which there is no effective treatment for 
advanced disease (Lee, 1976;  Clark et al., 1984; 
Franceschi et al., 1991). The dramatic increase in 
melanoma incidence has continued with 40,300 new 
invasive cases this year alone (Salopek et al., 1995; Rigel 
et al., 1996; Landis et al., 1998). The lifetime risk of an 
American developing an invasive melanoma had reached 
one in 87 (one in 70 for white males) (Rigel et al., 1996). 
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The incidence of melanoma is currently rising faster than 
any other cancer in men and second only to lung cancer 
in women (Halaban, 1993; Barnhill et al., 1993; Kosary, 
1995; Rigel, 1996). Further, the mortality rate of 
melanoma is rising at a rate second only to that of lung 
cancer (Henderson et al., 1991; Kosary, 1995; Rigel, 
1996), and the American Cancer Society predicts that 
there will be 7300 deaths from the disease in 1998 
(Landis et al., 1998). 
There are a number of well-defined clinical and 
pathological stages of melanoma progression and 
metastasis. For example, normal melanocytes can give 
rise to precancerous lesions known as benign, atypical 
melanocytic nevi, the vast majority of which eventually 
regress (Clark et al., 1984; Clark, 1991; Herlyn, 1993). 
Occasionally, however, a nevus can progress to a radial 
growth phase (RGP) primary melanoma (Clark, 1991; 
Guerry et al., 1993). These lesions are rather indolent 
and confined primarily to the epidermis ('melanoma in 
situ'), as they tend to expand in a horizontal plaque 
manner (Clark, 1991;  Guerry et al., 1993).  RGP 
melanomas are almost always cured by surgical excision 
and presumably consist of tumors that are not competent 
for metastasis (Clark, 1991; Guerry et al., 1993). Slowly 
growing RGP melanomas can evolve over long periods 
of time and eventually change to the more rapidly 
growing vertical growth phase (VGP) primary 
melanoma (Clark, 1991). Such lesions penetrate the 
basement membrane separating the epidermis from 
underlying mesenchyme and contain progressively 
greater proportions of metastatically competent 
melanoma cells that can readily proliferate in different 
organ environments (Clark, 1991). The final phase of 
melanoma progression is the formation of distant organ 
metastases, particularly from primary lesions greater 
than 0.76 mm in thickness (Clark et al., 1984; Clark, 
1991; Franceschi et al., 1991; Henderson et al., 1991; 
Barnhill et al., 1993; Halaban, 1993; Herlyn, 1993; 
Kosary, 1995; Salopek et al., 1995; Rigel, 1996; Rigel et 
al., 1996; Landis et al., 1998). 
The etiology, progression, diagnosis and therapy of 
malignant melanoma have been intensely investigated 
(Herlyn et al., 1987; Holzmann et al., 1987; Herlyn, 






